229 related articles for article (PubMed ID: 34399381)
1. Comparing mortality in patients with carbapenemase-producing carbapenem resistant Enterobacterales and non-carbapenemase-producing carbapenem resistant Enterobacterales bacteremia.
Hovan MR; Narayanan N; Cedarbaum V; Bhowmick T; Kirn TJ
Diagn Microbiol Infect Dis; 2021 Dec; 101(4):115505. PubMed ID: 34399381
[TBL] [Abstract][Full Text] [Related]
2. Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.
Tamma PD; Goodman KE; Harris AD; Tekle T; Roberts A; Taiwo A; Simner PJ
Clin Infect Dis; 2017 Feb; 64(3):257-264. PubMed ID: 28013264
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia.
Seo H; Lee SC; Chung H; Ra SH; Sung H; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Woo JH; Chong YP
Int J Antimicrob Agents; 2020 Oct; 56(4):106126. PubMed ID: 32755654
[TBL] [Abstract][Full Text] [Related]
4. Clinical and molecular characteristics and risk factors for patients acquiring carbapenemase-producing and non-carbapenemase-producing carbapenem-nonsusceptible-Enterobacterales bacteremia.
Wu AY; Chang H; Wang NY; Sun FJ; Liu CP
J Microbiol Immunol Infect; 2022 Dec; 55(6 Pt 2):1229-1238. PubMed ID: 34824020
[TBL] [Abstract][Full Text] [Related]
5. Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant
Cancelli F; Oliva A; De Angelis M; Mascellino MT; Mastroianni CM; Vullo V
Biomed Res Int; 2018; 2018():2785696. PubMed ID: 30581848
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for acquisition of carbapenemase-producing versus non-carbapenemase-producing enterobacterales: a case-control study.
Hassoun-Kheir N; Hussein K; Karram M; Saffuri M; Badaan S; Peleg S; de Kraker MEA; Aboelhega W; Warman S; Alon T; Eluk O; Geffen Y; Paul M
Clin Microbiol Infect; 2023 May; 29(5):629-634. PubMed ID: 36641053
[TBL] [Abstract][Full Text] [Related]
7. Treatment and Outcomes of Infections Caused by Diverse Carbapenemase-Producing Carbapenem-Resistant
Lim FK; Liew YX; Cai Y; Lee W; Teo JQM; Lay WQ; Chung J; Kwa ALH
Front Cell Infect Microbiol; 2020; 10():579462. PubMed ID: 33178629
[No Abstract] [Full Text] [Related]
8. Retrospective Observational Study from a Chinese Network of the Impact of Combination Therapy versus Monotherapy on Mortality from Carbapenem-Resistant
Wang X; Wang Q; Cao B; Sun S; Zhang Y; Gu B; Li B; Liao K; Zhao F; Jin L; Jin C; Yang C; Pei F; Zhang Z; Wang H
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30348660
[TBL] [Abstract][Full Text] [Related]
9. Performance evaluation of automated BD Phoenix NMIC-500 panel for carbapenemase detection in carbapenem-resistant and carbapenem-susceptible Enterobacterales.
Cho H; Kim JO; Choi JE; Lee H; Heo W; Cha YJ; Yoo IY; Park YJ
J Microbiol Methods; 2020 Oct; 177():106042. PubMed ID: 32890572
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors and Molecular Epidemiology of Complicated Intra-Abdominal Infections With Carbapenem-Resistant Enterobacteriaceae: A Multicenter Study in China.
Liu J; Zhang L; Pan J; Huang M; Li Y; Zhang H; Wang R; Zhao M; Li B; Liu L; Gong Y; Bian J; Li X; Tang Y; Lei M; Chen D
J Infect Dis; 2020 Mar; 221(Suppl 2):S156-S163. PubMed ID: 32176797
[TBL] [Abstract][Full Text] [Related]
11. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival.
Balkan II; Aygün G; Aydın S; Mutcalı SI; Kara Z; Kuşkucu M; Midilli K; Şemen V; Aras S; Yemişen M; Mete B; Özaras R; Saltoğlu N; Tabak F; Öztürk R
Int J Infect Dis; 2014 Sep; 26():51-6. PubMed ID: 24998423
[TBL] [Abstract][Full Text] [Related]
12. Comparison of four low-cost carbapenemase detection tests and a proposal of an algorithm for early detection of carbapenemase-producing Enterobacteriaceae in resource-limited settings.
Kumudunie WGM; Wijesooriya LI; Wijayasinghe YS
PLoS One; 2021; 16(1):e0245290. PubMed ID: 33434203
[TBL] [Abstract][Full Text] [Related]
13. Performance of the BD Phoenix CPO detect assay for detection and classification of carbapenemase-producing organisms.
Berneking L; Both A; Berinson B; Hoffmann A; Lütgehetmann M; Aepfelbacher M; Rohde H
Eur J Clin Microbiol Infect Dis; 2021 May; 40(5):979-985. PubMed ID: 33245470
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes and Treatment Strategies in Patients With Non-Carbapenemase-producing Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacterales Infections.
Debnath A; Pillinger KE; Martin AJ; Dobrzynski D; Cameron A; Shulder S
Ann Pharmacother; 2023 Jul; 57(7):803-812. PubMed ID: 36268974
[TBL] [Abstract][Full Text] [Related]
15. Systematic Analysis of Mobile Genetic Elements Mediating β-Lactamase Gene Amplification in Noncarbapenemase-Producing Carbapenem-Resistant
Shropshire WC; Konovalova A; McDaneld P; Gohel M; Strope B; Sahasrabhojane P; Tran CN; Greenberg D; Kim J; Zhan X; Aitken S; Bhatti M; Savidge TC; Treangen TJ; Hanson BM; Arias CA; Shelburne SA
mSystems; 2022 Oct; 7(5):e0047622. PubMed ID: 36036505
[TBL] [Abstract][Full Text] [Related]
16. Molecular Epidemiology of Carbapenem-Resistant Enterobacterales Strains Isolated from Blood Cultures in Antalya, Turkey.
Su HR; Turhan Ö; Erman Daloğlu CA; Öğünç MD; Özhak B; Öngüt G; Kuşkucu MA; Midilli K; Mamıkoğlu L
Lab Med; 2020 Nov; 51(6):601-605. PubMed ID: 32383446
[TBL] [Abstract][Full Text] [Related]
17. Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae.
Marimuthu K; Ng OT; Cherng BPZ; Fong RKC; Pada SK; De PP; Ooi ST; Smitasin N; Thoon KC; Krishnan PU; Ang MLT; Chan DSG; Kwa ALH; Deepak RN; Chan YK; Chan YFZ; Huan X; Zaw Linn K; Tee NWS; Tan TY; Koh TH; Lin RTP; Hsu LY; Sengupta S; Paterson DL; Perencevich E; Harbarth S; Teo J; Venkatachalam I;
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383670
[TBL] [Abstract][Full Text] [Related]
18. Meropenem-Vaborbactam Activity against Carbapenem-Resistant
Castanheira M; Doyle TB; Kantro V; Mendes RE; Shortridge D
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712207
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
[TBL] [Abstract][Full Text] [Related]
20. Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018.
Perovic O; Ismail H; Quan V; Bamford C; Nana T; Chibabhai V; Bhola P; Ramjathan P; Swe Swe-Han K; Wadula J; Whitelaw A; Smith M; Mbelle N; Singh-Moodley A;
Eur J Clin Microbiol Infect Dis; 2020 Jul; 39(7):1287-1294. PubMed ID: 32124106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
